Paris, France, December 14, 2015 – SK Capital (“SK”), a private investment firm focused on the specialty materials, chemicals and healthcare sectors, announced that it has signed a definitive agreement to sell IBA Molecular (“IBAM” or the “Company”) to funds advised by CapVest Partners LP (“CapVest”). The transaction is expected to close at the end of Q1 2016.
IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe and Asia. IBAM has a unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The Company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications S.A.
Commenting on the agreement, Jamshid Keynejad, Chairman of IBA Molecular and a Founding Partner of SK Capital, said, “We are proud of what has been accomplished by IBA Molecular under our ownership and believe that the business has significant growth ahead under the continued leadership of Renaud Dehareng and his team. We are confident that CapVest will be a strong partner for IBAM as it moves into the next stage of its development. We wish CapVest, the management team and IBAM’s employees every success and are excited to follow their accomplishments in the years to come.”
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors. The firm’s purpose is to build strong and growing businesses that create substantial long-term economic value. SK utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio companies generate revenues of approximately $8 billion annually and employ approximately 9,000 people. The firm currently manages more than $1.5 billion of committed capital. For more information, please visit www.skcapitalpartners.com
CapVest is an established European mid-market private equity firm focused on acquiring market leading companies supplying essential products and services. The firm places an emphasis on driving business growth through active management and has demonstrated consistent success in creating long-term value. For more information, please visit www.capvest.co.uk